Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application

Journal of Controlled Release

Volumn 176, Issue 1, 2014, Pages 123-132

  He, Huining ^a,b   Ye, Junxiao ^c   Wang, Yinsong ^a   Liu, Quan ^c   Chung, Hee Sun ^d   Kwon, Young Min ^e   Shin, Meong Cheol ^d   Lee, Kyuri ^d   Yang, Victor C ^a,d,f  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c TIANJIN UNIVERSITY   (China)

^d UNIVERSITY OF MICHIGAN   (United States)

^e NOVA SOUTHEASTERN UNIVERSITY   (United States)

^f Seoul National University   (South Korea)

Author keywords

Acute lymphoblastic leukemia; Cell penetrating peptide; Encapsulation; Erythrocytes; Red blood cells

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; CELL-PENETRATING PEPTIDE; ENCAPSULATION METHODS; ENCAPSULATION OF PROTEINS; ERYTHROCYTES; LOW MOLECULAR WEIGHT PROTAMINES; PHYSICAL AND CHEMICAL PROPERTIES; RED BLOOD CELL;

BIODEGRADATION; CELL MEMBRANES; CYTOLOGY; DISEASES; ENCAPSULATION; PEPTIDES;

BLOOD;

ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ASPARAGINASE; CELL PENETRATING PEPTIDE; DRUG CARRIER; ERYTHROPOIETIN; HEMOGLOBIN; HYDROCORTISONE; OVALBUMIN; PRIMAQUINE; PROTAMINE; PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; BIODEGRADABILITY; CELL ENCAPSULATION; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ERYTHROCYTE; HUMAN; MOLECULAR WEIGHT; NONHUMAN; POROSITY; PRIORITY JOURNAL; REVIEW;

ACUTE LYMPHOBLASTIC LEUKEMIA; CELL PENETRATING PEPTIDE; ENCAPSULATION; ERYTHROCYTES; RED BLOOD CELLS;

ANIMALS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CELL-PENETRATING PEPTIDES; DRUG CARRIERS; ERYTHROCYTES; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84893452925     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.12.019     Document Type: Review

References (101)

1. L.N. Vandenberg, T. Colborn, T.B. Hayes, J.J. Heindel, D.R. Jacobs Jr., D.H. Lee, T. Shioda, A.M. Soto, F.S. vom Saal, W.V. Welshons, R.T. Zoeller, and J.P. Myers Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses Endocr. Rev. 33 2012 378 455
2. J. Zhang, and M.A. Lazar The mechanism of action of thyroid hormones Annu. Rev. Physiol. 62 2000 439 466 (Pubitemid 30618270)
3. C.B. Del Debbio, L.M. Tonon, and S.R. Secoli Monoclonal antibody therapy: a literature review Rev. Gaucha Enferm. 28 2007 133 142
4. O. Leavy Therapeutic antibodies: past, present and future Nat. Rev. Immunol. 10 2010 297
5. A.M. Scott, J.D. Wolchok, and L.J. Old Antibody therapy of cancer Nat. Rev. Cancer 12 2012 278 287
6. M.A. Cheever, and C.S. Higano PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine Clin. Cancer Res. 17 2011 3520 3526
7. J.L. Gulley, R.A. Madan, and C.R. Heery Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer Am. Soc. Clin. Oncol. Educ. Book 2013 2012 166 170
8. D.M. Lubaroff Prostate cancer vaccines in clinical trials Expert Rev. Vaccines 11 2012 857 868
9. C. Ogi, and A. Aruga Clinical evaluation of therapeutic cancer vaccines Hum. Vaccin. Immunother. 9 2013 1049 1057
10. P.J. Carter Introduction to current and future protein therapeutics: a protein engineering perspective Exp. Cell Res. 317 2011 1261 1269
11. Y. Huang, Y.S. Park, J. Wang, C. Moon, Y.M. Kwon, H.S. Chung, Y.J. Park, and V.C. Yang ATTEMPTS system: a macromolecular prodrug strategy for cancer drug delivery Curr. Pharm. Des. 16 2010 2369 2376
12. R. Haag, and F. Kratz Polymer therapeutics: concepts and applications Angew. Chem. Int. Ed. Engl. 45 2006 1198 1215 (Pubitemid 44097641)
13. L. Tang, A.M. Persky, G. Hochhaus, and B. Meibohm Pharmacokinetic aspects of biotechnology products J. Pharm. Sci. 93 2004 2184 2204 (Pubitemid 39129617)
14. M.L. Graham Pegaspargase: a review of clinical studies Adv. Drug Deliv. Rev. 55 2003 1293 1302 (Pubitemid 37464563)
15. S.J. Updike, R.T. Wakamiya, and E.N. Lightfoot Jr. Asparaginase entrapped in red blood cells: action and survival Science 193 1976 681 683
16. N.V. Katre, M.J. Knauf, and W.J. Laird Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model Proc. Natl. Acad. Sci. 84 1987 1487 1491 (Pubitemid 17066715)
17. Y. Tsutsumi, M. Onda, S. Nagata, B. Lee, R.J. Kreitman, and I. Pastan Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity Proc. Natl. Acad. Sci. 97 2000 8548 8553 (Pubitemid 30639710)
18. P. Bailon, A. Palleroni, C.A. Schaffer, C.L. Spence, W.J. Fung, J.E. Porter, G.K. Ehrlich, W. Pan, Z.X. Xu, M.W. Modi, A. Farid, W. Berthold, and M. Graves Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C Bioconjug. Chem. 12 2001 195 202 (Pubitemid 32235471)
19. F.M. Veronese, and G. Pasut PEGylation, successful approach to drug delivery Drug Discov. Today 10 2005 1451 1458 (Pubitemid 41483874)
20. R.B. Greenwald, Y.H. Choe, J. McGuire, and C.D. Conover Effective drug delivery by PEGylated drug conjugates Adv. Drug Deliv. Rev. 55 2003 217 250 (Pubitemid 36135917)
21. C.A. Buscaglia, J. Alfonso, O. Campetella, and A.C. Frasch Tandem amino acid repeats from Trypanosoma cruzi shed antigens increase the half-life of proteins in blood Blood 93 1999 2025 2032 (Pubitemid 29128505)
22. M.S. Dennis, M. Zhang, Y.G. Meng, M. Kadkhodayan, D. Kirchhofer, D. Combs, and L.A. Damico Albumin binding as a general strategy for improving the pharmacokinetics of proteins J. Biol. Chem. 277 2002 35035 35043
23. R.E. Kontermann Strategies to extend plasma half-lives of recombinant antibodies BioDrugs 23 2009 93 109
24. R. Jefferis Glycosylation as a strategy to improve antibody-based therapeutics Nat. Rev. Drug Discov. 8 2009 226 234
25. A.M. Sinclair, and S. Elliott Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins J. Pharm. Sci. 94 2005 1626 1635 (Pubitemid 41360859)
26. J.W. Baynes, and F. Wold Effect of glycosylation on the in vivo circulating half-life of ribonuclease J. Biol. Chem. 251 1976 6016 6024
27. S.A. Marshall, G.A. Lazar, A.J. Chirino, and J.R. Desjarlais Rational design and engineering of therapeutic proteins Drug Discov. Today 8 2003 212 221 (Pubitemid 36298676)
28. A. Yavlovich, B. Smith, K. Gupta, R. Blumenthal, and A. Puri Light-sensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications Mol. Membr. Biol. 27 2010 364 381
29. B. Thierry Drug nanocarriers and functional nanoparticles: applications in cancer therapy Curr. Drug Deliv. 6 2009 391 403
30. S. Sultana, M.R. Khan, M. Kumar, S. Kumar, and M. Ali Nanoparticles-mediated drug delivery approaches for cancer targeting: a review J. Drug Target. 21 2013 107 125
31. D.S. Pisal, M.P. Kosloski, and S.V. Balu-Iyer Delivery of therapeutic proteins J. Pharm. Sci. 99 2010 2557 2575
32. F.M. Veronese Peptide and protein PEGylation: a review of problems and solutions Biomaterials 22 2001 405 417 (Pubitemid 32007845)
33. E.T. Baran, N. Ozer, and V. Hasirci In vivo half life of nanoencapsulated l-asparaginase J. Mater. Sci. Mater. Med. 13 2002 1113 1121 (Pubitemid 36169448)
34. J.R. DeLoach Encapsulation of exogenous agents in erythrocytes and the circulating survival of carrier erythrocytes J. Appl. Biochem. 5 1983 149 157
35. U. Bilati, E. Allemann, and E. Doelker Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles Eur. J. Pharm. Biopharm. 59 2005 375 388 (Pubitemid 40342512)
36. B.S. Zolnik, and D.J. Burgess Effect of acidic pH on PLGA microsphere degradation and release J. Control. Release 122 2007 338 344 (Pubitemid 47404676)
37. H. Okada, Y. Inoue, T. Heya, H. Ueno, Y. Ogawa, and H. Toguchi Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate Pharm. Res. 8 1991 787 791
38. M.I. Garin, R.M. Lopez, S. Sanz, M. Pinilla, and J. Luque Erythrocytes as carriers for recombinant human erythropoietin Pharm. Res. 13 1996 869 874 (Pubitemid 26227744)
39. M. Magnani, L. Rossi, M. D'Ascenzo, I. Panzani, L. Bigi, and A. Zanella Erythrocyte engineering for drug delivery and targeting Biotechnol. Appl. Biochem. 28 Pt 1 1998 1 6 (Pubitemid 28369899)
40. M. Cremel, N. Guerin, F. Horand, A. Banz, and Y. Godfrin Red blood cells as innovative antigen carrier to induce specific immune tolerance Int. J. Pharm. 443 2013 39 49
41. L.M. Matovcik, I.G. Junga, and S.L. Schrier Drug-induced endocytosis of neonatal erythrocytes Blood 65 1985 1056 1063 (Pubitemid 15121925)
42. A. Joliot, C. Pernelle, H. Deagostini-Bazin, and A. Prochiantz Antennapedia homeobox peptide regulates neural morphogenesis Proc. Natl. Acad. Sci. 88 1991 1864 1868 (Pubitemid 21916327)
43. L. Rossi, S. Serafini, F. Pierige, A. Antonelli, A. Cerasi, A. Fraternale, L. Chiarantini, and M. Magnani Erythrocyte-based drug delivery Expert Opin. Drug Deliv. 2 2005 311 322 (Pubitemid 41130885)
44. C.G. Millan, M.L. Marinero, A.Z. Castaneda, and J.M. Lanao Drug, enzyme and peptide delivery using erythrocytes as carriers J. Control. Release 95 2004 27 49 (Pubitemid 38167677)
45. T.Y. Lee, Y.S. Park, G.A. Garcia, R.K. Sunahara, J.H. Woods, and V.C. Yang Cell permeable cocaine esterases constructed by chemical conjugation and genetic recombination Mol. Pharm. 9 2012 1361 1373
46. G. Gu, H. Xia, Q. Hu, Z. Liu, M. Jiang, T. Kang, D. Miao, Y. Tu, Z. Pang, Q. Song, L. Yao, H. Chen, X. Gao, and J. Chen PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy Biomaterials 34 2013 196 208
47. A.E. David, J. Gong, B. Chertok, R.C. Domszy, C. Moon, Y.S. Park, N.S. Wang, A.J. Yang, and V.C. Yang Immobilized thermolysin for highly efficient production of low-molecular-weight protamine - an attractive cell-penetrating peptide for macromolecular drug delivery applications J. Biomed. Mater. Res. A 100 2012 211 219
48. E. Apostolidou, R. Swords, Y. Alvarado, and F.J. Giles Treatment of acute lymphoblastic leukaemia: a new era Drugs 67 2007 2153 2171 (Pubitemid 47557092)
49. C.H. Pui, and W.E. Evans Treatment of acute lymphoblastic leukemia N. Engl. J. Med. 354 2006 166 178 (Pubitemid 43076714)
50. C. Langebrake, D. Reinhardt, and J. Ritter Minimising the long-term adverse effects of childhood leukaemia therapy Drug Saf. 25 2002 1057 1077 (Pubitemid 36013440)
51. http://www.cancer.gov/
52. J.M. Hill, J. Roberts, E. Loeb, A. Khan, A. MacLellan, and R.W. Hill l-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia JAMA 202 1967 882 888
53. F.F. Becker, and J.D. Broome l-asparaginase: inhibition of endogenous RNA polymerase activity in regenerating liver Arch. Biochem. Biophys. 130 1969 332 336
54. D.H. Ho, N.S. Brown, A. Yen, R. Holmes, M. Keating, A. Abuchowski, R.A. Newman, and I.H. Krakoff Clinical pharmacology of polyethylene glycol-l-asparaginase Drug Metab. Dispos. 14 1986 349 352 (Pubitemid 16037445)
55. H.J. Muller, and J. Boos Use of l-asparaginase in childhood ALL Crit. Rev. Oncol. Hematol. 28 1998 97 113 (Pubitemid 28390409)
56. H.F. Oettgen, L. Tallal, C.C. Tan, M.L. Murphy, B.D. Clarkson, R.D. Golbey, I.H. Krakoff, D.A. Karnofsky, and H.J. Burchenal Clinical experience with l-asparaginase Recent Results Cancer Res. 33 1970 219 235
57. http://www.man.poznan.pl/CBB/POSTER1/poster.html
58. D.A. Cooney, and R.E. Handschumacher l-asparaginase and l-asparagine metabolism Annu. Rev. Pharmacol. 10 1970 421 440
59. F.F. Becker, and J.D. Broome l-asparaginase: inhibition of early mitosis in regenerating rat liver Science 156 1967 1602 1603
60. J.C. Wriston Jr., and T.O. Yellin l-asparaginase: a review Adv. Enzymol. Relat. Areas Mol. Biol. 39 1973 185 248
61. G.M. Shepherd Hypersensitivity reactions to chemotherapeutic drugs Clin. Rev. Allergy Immunol. 24 2003 253 262 (Pubitemid 36584220)
62. A.D. Information Asparaginase 2001 American Society of Health System Pharmacists 872 875
63. M. Hamidi, and H. Tajerzadeh Carrier erythrocytes: an overview Drug Deliv. 10 2003 9 20 (Pubitemid 36205992)
64. S. Biagiotti, M.F. Paoletti, A. Fraternale, L. Rossi, and M. Magnani Drug delivery by red blood cells IUBMB Life 63 2011 621 631
65. G.M. Ihler, R.H. Glew, and F.W. Schnure Enzyme loading of erythrocytes Proc. Natl. Acad. Sci. U.S.A. 70 1973 2663 2666
66. R. Luo, S. Mutukumaraswamy, S.S. Venkatraman, and B. Neu Engineering of erythrocyte-based drug carriers: control of protein release and bioactivity J. Mater. Sci. Mater. Med. 23 2012 63 71
67. F. Pierige, S. Serafini, L. Rossi, and M. Magnani Cell-based drug delivery Adv. Drug Deliv. Rev. 60 2008 286 295 (Pubitemid 350236405)
68. L. Zolla, G. Lupidi, M. Marcheggiani, G. Falcioni, and M. Brunori Red blood cells as carriers for delivering of proteins Ann. Ist. Super. Sanita. 27 1991 97 103
69. C. Lizano, S. Sanz, J. Luque, and M. Pinilla In vitro study of alcohol dehydrogenase and acetaldehyde dehydrogenase encapsulated into human erythrocytes by an electroporation procedure Biochim. Biophys. Acta 1425 1998 328 336 (Pubitemid 28493342)
70. C.H. Fu, and K.M. Sakamoto PEG-asparaginase Expert. Opin. Pharmacother. 8 2007 1977 1984 (Pubitemid 47316151)
71. V.I. Avramis, S. Sencer, A.P. Periclou, H. Sather, B.C. Bostrom, L.J. Cohen, A.G. Ettinger, L.J. Ettinger, J. Franklin, P.S. Gaynon, J.M. Hilden, B. Lange, F. Majlessipour, P. Mathew, M. Needle, J. Neglia, G. Reaman, J.S. Holcenberg, and L. Stork A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study Blood 99 2002 1986 1994 (Pubitemid 34525479)
72. F.K. Alanazi, D. Harisa Gel, A. Maqboul, M. Abdel-Hamid, S.H. Neau, and I.A. Alsarra Biochemically altered human erythrocytes as a carrier for targeted delivery of primaquine: an in vitro study Arch. Pharm. Res. 34 2011 563 571
73. M. Foroozesh, M. Hamidi, A. Zarrin, S. Mohammadi-Samani, and H. Montaseri Preparation and in-vitro characterization of tramadol-loaded carrier erythrocytes for long-term intravenous delivery J. Pharm. Pharmacol. 63 2011 322 332
74. C. Lizano, M.T. Perez, and M. Pinilla Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation Life Sci. 68 2001 2001 2016 (Pubitemid 32245601)
75. C. Lizano, V. Weissig, V.P. Torchilin, P. Sancho, A.I. Garcia-Perez, and M. Pinilla In vivo biodistribution of erythrocytes and polyethyleneglycol- phosphatidylethanolamine micelles carrying the antitumour agent dequalinium Eur. J. Pharm. Biopharm. 56 2003 153 157 (Pubitemid 37072097)
76. V.R. Muzykantov Drug delivery by red blood cells: vascular carriers designed by mother nature Expert Opin. Drug Deliv. 7 2010 403 427
77. F.I. Ataullakhanov, V.M. Vitvitskii, A.M. Zhabotinskii, and A.V. Pichugin Permeability of human erythrocytes to asparagine Biokhimiia 50 1985 1733 1737 (Pubitemid 16219985)
78. V.I. Avramis, and E.H. Panosyan Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future Clin. Pharmacokinet. 44 2005 367 393 (Pubitemid 40663683)
79. M. Hamidi, N. Zarei, A. Zarrin, and S. Mohammadi-Samani Preparation and validation of carrier human erythrocytes loaded by bovine serum albumin as a model antigen/protein Drug Deliv. 14 2007 295 300 (Pubitemid 47027042)
80. R.A. Chalmers Comparison and potential of hypo-osmotic and iso-osmotic erythrocyte ghosts and carrier erythrocytes as drug and enzyme carriers Bibl. Haematol. 1985 15 24
81. C. Bachran, I. Heisler, H. Fuchs, and M. Sutherland Influence of protein transduction domains on target-specific chimeric proteins Biochem. Biophys. Res. Commun. 337 2005 602 609 (Pubitemid 41429327)
82. G.P. Dietz, and M. Bahr Delivery of bioactive molecules into the cell: the Trojan horse approach Mol. Cell. Neurosci. 27 2004 85 131 (Pubitemid 39370094)
83. T. Suzuki, S. Futaki, M. Niwa, S. Tanaka, K. Ueda, and Y. Sugiura Possible existence of common internalization mechanisms among arginine-rich peptides J. Biol. Chem. 277 2002 2437 2443 (Pubitemid 34953265)
84. N. Schmidt, A. Mishra, G.H. Lai, and G.C. Wong Arginine-rich cell-penetrating peptides FEBS Lett. 584 2010 1806 1813
85. C. De Coupade, A. Fittipaldi, V. Chagnas, M. Michel, S. Carlier, E. Tasciotti, A. Darmon, D. Ravel, J. Kearsey, M. Giacca, and F. Cailler Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules Biochem. J. 390 2005 407 418 (Pubitemid 41337102)
86. S.R. Schwarze, A. Ho, A. Vocero-Akbani, and S.F. Dowdy In vivo protein transduction: delivery of a biologically active protein into the mouse Science 285 1999 1569 1572 (Pubitemid 29420581)
87. L. Cao, J. Si, W. Wang, X. Zhao, X. Yuan, H. Zhu, X. Wu, J. Zhu, and G. Shen Intracellular localization and sustained prodrug cell killing activity of TAT-HSVTK fusion protein in hepatocelullar carcinoma cells Mol. Cells 21 2006 104 111
88. G. Elliott, and P. O'Hare Intercellular trafficking and protein delivery by a herpes virus structural protein Cell 88 1997 223 233 (Pubitemid 28015871)
89. L.C. Chang, H.F. Lee, Z. Yang, and V.C. Yang Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization AAPS PharmSci 3 2001 E17
90. Y.J. Park, L.C. Chang, J.F. Liang, C. Moon, C.P. Chung, and V.C. Yang Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study FASEB J. 19 2005 1555 1557 (Pubitemid 41279029)
91. Y. Byun, V.K. Singh, and V.C. Yang Low molecular weight protamine: a potential nontoxic heparin antagonist Thromb. Res. 94 1999 53 61 (Pubitemid 29170400)
92. L.C. Chang, J.F. Liang, H.F. Lee, L.M. Lee, and V.C. Yang Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity AAPS PharmSci 3 2001 E18
93. R. Kharidia, K.A. Friedman, and J.F. Liang Improved gene expression using low molecular weight peptides produced from protamine sulfate Biochemistry (Mosc) 73 2008 1162 1168
94. Y.S. Choi, J.Y. Lee, J.S. Suh, Y.M. Kwon, S.J. Lee, J.K. Chung, D.S. Lee, V.C. Yang, C.P. Chung, and Y.J. Park The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine Biomaterials 31 2010 1429 1443
95. L.M. Lee, L.C. Chang, S. Wrobleski, T.W. Wakefield, and V.C. Yang Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model AAPS PharmSci 3 2001 E19
96. Y.S. Park, A.E. David, Y. Huang, J.B. Park, H. He, Y. Byun, and V.C. Yang In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1alpha oligonucleotide to adipose tissue reduces adiposity in obese mice J. Control. Release 161 2012 1 9
97. H. Xia, X. Gao, G. Gu, Z. Liu, N. Zeng, Q. Hu, Q. Song, L. Yao, Z. Pang, X. Jiang, J. Chen, and H. Chen Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration Biomaterials 32 2011 9888 9898
98. H. He, J. Sheng, A.E. David, Y.M. Kwon, J. Zhang, Y. Huang, J. Wang, and V.C. Yang The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption Biomaterials 34 2013 7733 7743
99. J.K. Choi, J.H. Jang, W.H. Jang, J. Kim, I.H. Bae, J. Bae, Y.H. Park, B.J. Kim, K.M. Lim, and J.W. Park The effect of epidermal growth factor (EGF) conjugated with low-molecular-weight protamine (LMWP) on wound healing of the skin Biomaterials 33 2012 8579 8590
100. Y.J. Park, J.F. Liang, K.S. Ko, S.W. Kim, and V.C. Yang Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study J. Gene Med. 5 2003 700 711 (Pubitemid 40309708)
101. Y.M. Kwon, H.S. Chung, C. Moon, J. Yockman, Y.J. Park, S.D. Gitlin, A.E. David, and V.C. Yang l-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL) J. Control. Release 139 2009 182 189